Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Talsaclidine
Drug: Propranolol

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264093

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBX 245 CL- fasted
Drug: BIBX 245 CL - fed

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02264197

Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIIL 284 oral solution
Drug: BIIL 284 wetability improved formulation (WIF) tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 95

Registration Number: NCT02265302

Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]talsaclidine, iv
Drug: [14C]talsaclidine, oral

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT02264054

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Talsaclidine
Drug: Placebo

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02264067

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine, high, film-coated tablets
Drug: Moxifloxacin, film-coated tablets
Drug: Cilobradine, low, film-coated tablets
Drug: Placebo, film-coated tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 125

Registration Number: NCT02264015

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine high dose 1
Drug: Placebo
Drug: Cilobradine low dose 1
Drug: Cilobradine high dose 2
Drug: Cilobradine low dose 2
Drug: Cilobradine medium dose
Drug: Metoprolol succinate tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 119

Registration Number: NCT02264002

Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tamsulosin HCl
Drug: Ketoconazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264171

Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban
Drug: Clopidogrel

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02265289

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan /HCTZ - compression tablet (DC)
Drug: Telmisartan /HCTZ - dry granulation tablet (DG)
Drug: Telmisartan /HCTZ - present commercial formulation

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02262572

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy